ADC Therapeutics S.A.
ADCT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -12.8% | -18.2% | 36.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 92.7% | 95.6% | 91.1% | 91.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -167.1% | -220.6% | -111.5% | -111.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -249.4% | -300.7% | -167.6% | -181.7% |
| EPS Diluted | -0.3 | -0.5 | -0.36 | -0.29 |
| % Growth | 40% | -38.9% | -24.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |